The study of phase 1 randomized -sponsored by BioNTech and held in USA– is designed to assess the securitythe immunogenicity and the optimal dose level of this combination vaccine. Meanwhile, the goal is to enroll 180 healthy volunteers from 18 to 64 years of agewith a follow-up period of each participant of six months.
“The flexibility Y speed manufacturing of mRNA technology has shown that it is adequate for other respiratory illnesses,” said Annaliesa AndersonSenior Vice President and Chief Scientific Officer of Vaccine Research and Development of Pfizer in a statement released by the companies.
He added that “even with existing seasonal influenza vaccines, the burden of this virus is serious all over the world and causes thousands of deaths and hospitalizations every year.
For its part, Ugur SahinCEO and co-founder of BioNTech, said, “By combining both indications into one vaccine approach, our goal is to give people a efficient way to receive immunization against two serious respiratory diseases with evolving viruses that require an adaptation of the vaccine”.
He also added that “the data will also provide us with more information about the potential of mRNA vaccines to address more than one pathogen.
This is the fourth collaboration between Pfizer and BioNTech in the field of infectious diseases, after the one they carried out for the influenza vaccine started in 2018which was followed by the one they developed for the vaccine against Covid-19 started in 2020 and another for the vaccine against Herpes zoster started in 2022.
Source: Ambito
David William is a talented author who has made a name for himself in the world of writing. He is a professional author who writes on a wide range of topics, from general interest to opinion news. David is currently working as a writer at 24 hours worlds where he brings his unique perspective and in-depth research to his articles, making them both informative and engaging.
